In a recent scientific article, published in the February issue of The FASEB Journal, InSight scientists in collaboration with researchers from leading institutions, demonstrate for the first time the wound healing potential of recombinant Heparanase.

Topical administration of recombinant heparanase was shown to significantly accelerate wound healing in a flap/punch model in mice and markedly improved flap survival in rats. These heparanase effects were associated with enhanced wound epithelialization and blood vessel maturation. Similarly, a marked elevation in wound angiogenesis, evaluated by MRI analysis and histological analyses, was observed in heparanase-over expressing transgenic mice.

InSight is committed to the development of recombinant heparanase for the treatment of chronic wounds. Impaired wound healing is a problem for the elderly, diabetics, immunosuppressed and immobilized individuals. The cost of treating all chronic wounds is estimated at $5 to $7 billion per year and is expected to increase 10% annually.